{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:59:19Z","timestamp":1780437559359,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":9828,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[1981,8]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:bold>Summary: <\/jats:bold> Steady\u2010state plasma valproate (VPA) levels were analyzed in 37 children after 6 weeks of VPA therapy. Twenty\u2010six patients were receiving other antiepileptic drugs in addition to VPA (experimental group). Eleven patients who received VPA alone served as controls. The mean VPA dose was not statistically different for the two groups (experimental group, 35.4 mg\/kg\/ day, 11.6 SD; control group, 31.1 mg\/kg\/day, SD 6.6) The mean plasma VPA level was significantly lower for the experimental group (63.0 \u03bcg\/m1, SD 21.8) than for the control (99.3 \u03bcg\/m1), SD 23.3) (<jats:italic>p<\/jats:italic> &lt; 0.01). VPA levelrdose ratio (LDR) was also reduced in the experimental group (1.92, SD 0.75) as compared to controls (3.26, SD 0.65) (<jats:italic>p<\/jats:italic> &lt; 0.01). Within the experimental group the VPA levels and VPA LDR were significantly reduced in patients receiving either phenytoin or phenobarbital. The data suggest that other antiepileptic drugs significantly alter the steady\u2010state level to dose relationship for VPA.<\/jats:p><\/jats:sec><jats:sec><jats:title>R\u00c9SUM\u00c9<\/jats:title><jats:p>Le taux plasmatique \u00e0 l'\u00e9quilibre du valproate de sodium (VPA) a \u00e9t\u00e9\u00e9tudi\u00e9 chez 37 enfants apr\u00e8s 6 semaines de th\u00e9rapeutique. Vingt six patients re\u00e7oivent d'autres m\u00e9dicaments anti\u00e9pileptiques associ\u00e9s au VPA (groupe exp\u00e9rimental) alors que 11 sujets t\u00e9moins ne re\u00e7oivent que le VPA seul. La posologie moyenne du VPA n'est pas significativement diff\u00e9rente entre les deux groupes (35,4 mg\/kg\/jour \u00b1 11,6 centre 31,1 mg\/kg\/jour \u00b1 6,6). Le taux plasmatique de VPA est significativement plus bas dans le groupe experimental (63,0 \u03bcg\/ml \u00b1 21,8) contre 99,3 \u03bcg\/ml \u00b1 23,3 dans le groupe t\u00e9moin (<jats:italic>p<\/jats:italic> &lt; 0,01). Le rapport taux plasmatique\/posologie (LDR) a \u00e9t\u00e9 diminu\u00e9 dans le groupe exp\u00e9rimental (1,92 \u00b1 0,75) par rapport au groupe t\u00e9moin (3,26 \u00b1 0,65), <jats:italic>p<\/jats:italic> &lt; 0,01 en particulier chez les malades recevant de la ph\u00e9nyto\u00efne ou du ph\u00e9nobarbital. La posologie moyenne du VPA n'\u00e9tant pas significativement diff\u00e9rente dans les deux groupes, les faits observ\u00e9s sugg\u00e8rent que l'addition d'autres anti\u00e9pileptiques est capable de modifier le taux \u00e0 l'\u00e9quilibre du VPA plasmatique en fonction de la dose administr\u00e9e.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESUMEN<\/jats:title><jats:p>Se analizaron los niveles estables de valproato en plasma (VPA) en 37 ni\u00f1os despu\u00e9s de 6 semanas de terapia con VPA. Ventiseis pacientes recib\u00edan otros f\u00e1rmacos adem\u00e1s de VPA (grupo experimental) y once s\u00f3lo tomaban VPA y sirvieron como controles. La dosis media de VPA no fue significativamente distinta en los dos grupos (grupo experimental: 35,4 mg\/kg\/d\u00eda, DS 11,6; grupo control: 31.1 mg\/kg\/d\u00eda, DS 6,6). El nivel plasm\u00e1tico medio de VPA fue significativamente inferior en el grupo experimental (63,0 \u03bcg\/ml, DS 21,8) que en el control (99,3 \u03bcg\/ml, DS 23,3), <jats:italic>p<\/jats:italic> &lt; 0,01. La relaci\u00f3n nivel de VPA: dosis (LDR) estaba tambi\u00e9n reducida en el grupo experimental (1,92, DS 0,75) al compararla con los controles (3,26, DS 0,65), <jats:italic>p<\/jats:italic> &lt; 0,01. Dentro del grupo experimental los niveles de VPA y la LDR estaban significativamente reducidos en pacientes que tomaban fenito\u00edna o fenobarbital. La dosis media no fue diferente entre los grupos experimental y control. Estos datos sugieren que la ingesti\u00f3n de otros f\u00e1rmacos alteran de modo significativo los niveles estables de VPA en relaci\u00f3n con la dosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>ZUSAMMENFASSUNG<\/jats:title><jats:p>In steady\u2010state befindliche Plasma Valproatspiegel (VPA) wurden bei 37 Kindern nach 6 w\u00f6chiger VPA\u2010Therapie analysiert. 26 Patienten erhielten zus\u00e4tzlich zum VPA andere Antiepileptika (experimentelle Gruppe). 11 Patienten, die VPA alleine bekamen, dienten als Kontrollen. Die mittlere VPA\u2010Dosis war in beiden Gruppen nicht signifikant Vunterschiedlich (experimentelle Gruppe 35,4 mg\/kg pro Tag, 11,6 SD; Kontrollgruppe 31,1 mg\/kg pro Tag, SD 6,6). Der mittlere Plasma VPA\u2010Spiegel war signifikant niedriger in der experimentellen Gruppe (63,0 \u03bcg\/ml, SD 21,8) als in der Kontrollgruppe (99,3 \u03bcg\/m1, SD 23,3), <jats:italic>p<\/jats:italic> &lt; 0.01. Das Verh\u00e4ltnis VPA\u2010Spiegel: Dosis (LDR) war in der experimentellen Gruppe ebenfalls reduziert (1,92, SD 0,75) gegenuber der Kontrollgruppe (3,26, SD 0,65), <jats:italic>p<\/jats:italic> &lt; 0.01. Innerhalb der experimentellen Gruppe waren die VPA\u2010Spiegel und die VPA\/LDR bei Patienten, die entweder Phenytoin oder Phenobarbital bekamen, signifikant erniedrigt. Die mittlere VPA\u2010Dosis war nicht signifikant unterschiedlich in der experimentellen und in der Kontrollgruppe. Diese Daten lassen vermuten, da\u00df andere Antiepileptika signifikanterweise den Steady\u2010state\u2010Spiegel im Hinblick auf die verabfolgte Dosis VPA \u00e4ndern.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1528-1157.1981.tb06154.x","type":"journal-article","created":{"date-parts":[[2007,11,21]],"date-time":"2007-11-21T13:23:05Z","timestamp":1195651385000},"page":"437-441","source":"Crossref","is-referenced-by-count":56,"title":["Reduction of Steady\u2010State Valproate Levels by Other Antiepileptic Drugs"],"prefix":"10.1111","volume":"22","author":[{"given":"J. Chris","family":"Sackellares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. E.","family":"Dreifuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Kiffin","family":"Penry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_1_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1979265629"},{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.29.6.904"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-197901000-00011"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1977.tb04462.x"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb01652.x"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198005010-00002"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977216736"},{"key":"e_1_2_1_8_1","first-page":"147","volume-title":"Antiepileptic Drugs: Quantitative Analysis and Interpretation","author":"Kupferberg HJ.","year":"1978"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410070613"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410030105"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb00871.x"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.40.6.570"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb01663.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197713020-00001"},{"key":"e_1_2_1_15_1","first-page":"78","volume-title":"Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy","author":"Richens A.","year":"1976"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561557"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1975.tb04738.x"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1978.tb00653.x"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103518"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.28.9.892"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1157.1981.tb06154.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1157.1981.tb06154.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T11:42:35Z","timestamp":1698925355000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1157.1981.tb06154.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1981,8]]}},"alternative-id":["10.1111\/j.1528-1157.1981.tb06154.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1157.1981.tb06154.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[1981,8]]}}}